| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.0019 | 0.9 |
| mRNA | Tamoxifen | GDSC1000 | pan-cancer | AAC | -0.0021 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.0017 | 1 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0018 | 1 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.0015 | 1 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.0044 | 1 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.0015 | 1 |